Now Entering Russ's World
Once again cancer drug company Seattle Genetics is the topic of conversation. The trailblazing company continues to show why the Puget Sound area in the state of Washington, is one of the leading cancer research communities in the United States. Seattle Genetics has had a meteoric rise since it was founded and currently shows no signs of stopping its incline anytime soon.
Seattle Genetics is in the process of expanding the use of its drug Adcetris, and broaden its drug pipeline with new drugs. Because Adcetris is Seattle Genetics first commercialized drug, it really putting it out there to the masses.
Ambitious moves like these can cause a company to seemingly bust at the seems. Knowing this the cancer company has already started up another hiring spree to compensate for its growth.
Company CEO Clay Siegall claims that the company is putting their drug Adcetris in as many cancer treatment scenarios as possible. According to Siegall the drug has already been tested in dozens of trials against different types of lymphomas. Siegall also claims that the company has very high hopes for the drug moving forward, but in reality the company’s still executing the early stages of its end goal.
About Clay Siegall
Clay Siegall is the co-founder and CEO of Seattle Genetics, as well as the company’s President and member of the Board of Directors. Under the guidance of Siegall, the cancer company has made a huge impact in the cancer research community in a relatively short amount of time. He was a major component of the company securing of hundreds of millions of dollars through public and private financing.